Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a ...
格隆汇10月16日丨仙琚制药(002332.SZ)公布,公司于近日收到国家药品监督管理局下发的甲磺酸倍他司汀片境内生产药品注册受理通知书。
Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a ...